Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Jittamala P. et al, (2024)

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of phase 2 antiviral studies

Wongnak P. et al, (2024)

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Luvira V. et al, (2024), BMC Infectious Diseases, 24

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Schilling WHK. et al, (2024), The Lancet Infectious Diseases, 24, 36 - 45

Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)

Jittamala P. et al, (2023), The Journal of Infectious Diseases, 228, 1318 - 1325

Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger.

Kabore Y. et al, (2023), The American journal of tropical medicine and hygiene, 109, 511 - 514

Raising awareness of antimicrobial resistance: development of an ‘antibiotic footprint calculator’

Prapharsavat R. et al, (2023), Journal of Antimicrobial Chemotherapy, 78, 1317 - 1321

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial

Luvira V. et al, (2023)

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

Schilling WHK. et al, (2023), eLife, 12

Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study

Perrone C. et al, (2022), Wellcome Open Research, 6, 216 - 216

Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study

Perrone C. et al, (2022)

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants

Jittamala P. et al, (2022)

Antimicrobial resistance patterns in bacteria causing febrile illness in Africa, South Asia, and Southeast Asia: a systematic review of published etiological studies from 1980-2015

Roberts T. et al, (2022), International Journal of Infectious Diseases, 122, 612 - 621

Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19

Schilling WHK. et al, (2022)

Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project

Chandna A. et al, (2022), Wellcome Open Research, 6, 64 - 64

Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project

Chandna A. et al, (2022), Wellcome Open Research, 6, 64 - 64

Improving empiric antibiotic prescribing in pediatric bloodstream infections: a potential application of weighted-incidence syndromic combination antibiograms (WISCA)

Cook A. et al, (2022), Expert Review of Anti-infective Therapy, 20, 445 - 456

The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions

Schilling WHK. et al, (2021), Wellcome Open Research, 6, 71 - 71

Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study

Perrone C. et al, (2021), Wellcome Open Research, 6, 216 - 216

Does hydroxychloroquine still have any role in the COVID-19 pandemic?

Schilling WH. and White NJ., (2021), Expert opinion on pharmacotherapy, 22, 1257 - 1266

Load More

Include forthcoming?